Compare Arqit Quantum Inc (ARQQ) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arqit Quantum Inc vs Quest Diagnostics Inc — how do they compare? Arqit Quantum Inc trades at $23.52 (market cap $424.79M), while Quest Diagnostics Inc trades at $237.51 (market cap $26.21B). The key difference: Quest Diagnostics Inc is far larger — about 61.7× Arqit Quantum Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Arqit Quantum Inc pays none. Which is the better fit depends on your goals.
| ARQQ | DGX | |
|---|---|---|
Market Cap | $424.79M | $26.21B |
Sector | Technology | Health |
52-Week High | $58.27 | $238.50 |
52-Week Low | $11.78 | $173.49 |
Enterprise Value | $398.10M | $31.97B |
Dividend Yield | — | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARQQ trades at $23.72, up 4.91% today, with a bullish technical signal from moving averages despite overbought RSI readings. The company shows explosive revenue growth but deep losses, with a P/S ratio of 352.9 reflecting high growth expectations. Recent news highlights a proof-of-concept with nLighten and strong H1 2026 revenue growth of 829% year-over-year, signaling commercial traction in quantum-safe encryption.
Outlook hinges on scaling revenue to offset high costs, with analyst sentiment split evenly between Buy and Hold. Key risks include sustained cash burn and competitive pressure, but government and telecom deals offer upside if execution improves.
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arqit Quantum Inc
Arqit Quantum provides advanced cybersecurity software that uses symmetric key agreement technology. Its solutions protect networked devices and data against current and future cyber threats, including quantum attacks.
Read more on ARQQ →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
